Latanoprost/Timolol Aurovitas (Timolol Maleate, Latanoprost)

Latanoprost increases the outflow of aqueous humor through the uveoscleral pathway by activating prostaglandin F receptors, while Timolol blocks beta‑adrenergic receptors to reduce aqueous humor production. The dual mechanism results in a greater overall decrease in intra‑ocular pressure than either component alone.

The dosing regimen for Latanoprost/Timolol Aurovitas is determined by the prescribing ophthalmologist based on the individual patient's condition, response, and tolerance. Typically, one drop is instilled into the affected eye(s) once daily, but the exact schedule must follow the prescriber’s instructions.

Safety data for Latanoprost/Timolol in pregnancy and lactation are limited. It should be used only if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Compared with single‑agent therapy, the Latanoprost/Timolol combination offers additive intra‑ocular pressure reduction because it targets both aqueous humor outflow and production. This often results in better pressure control for patients who do not achieve target levels with either prostaglandin analog or beta‑blocker alone.

Latanoprost/Timolol eye drops should be stored at room temperature, below 25 °C, in the original packaging. Protect the product from direct sunlight and moisture. Keep the bottle tightly closed when not in use and discard any solution that appears discolored or contains particles.

The medication is applied as a sterile ophthalmic solution. The patient should wash their hands, tilt the head back, pull down the lower eyelid, and place one drop into the conjunctival sac of the prescribed eye(s). Close the eye gently and avoid blinking excessively for a few seconds.

Serious risks include severe allergic reactions, bronchospasm in patients with asthma or COPD, marked bradycardia, hypotension, and ocular inflammation such as uveitis. Patients should seek immediate medical attention if they experience difficulty breathing, chest pain, rapid heartbeat changes, or significant eye pain.

The product is contraindicated in patients with known hypersensitivity to either component, those with severe sinus node dysfunction, uncontrolled asthma or COPD, and individuals using non‑selective beta‑blockers systemically. It should also be avoided in patients with certain cardiac conduction disorders unless specifically directed by a physician.